Analyzing speech to predict psychosis in at-risk patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify linguistic markers that may predict the transition to schizophrenia in patients at ultra-high risk. By utilizing computerized speech analysis techniques, including Latent Semantic Analysis, the study will analyze speech patterns from audio recordings of initial medical interviews. The goal is to validate a predictive model in the French language that can accurately forecast psychotic transitions based on subtle speech disorganization. The study will involve a longitudinal multicenter cohort approach to gather comprehensive data over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major and/or minor from 15 to 30 years old
* Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
* If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
* Affiliated with or beneficiary of a health insurance/social security system
* Able and willing to provide written informed consent

Exclusion Criteria:

* History of psychosis
* Risk of self-harm or violence not compatible with outpatient treatment
* QI\<70 (WAIS)
* Neurological disorder or major health problem
* Impossibility to interrupt neuroleptic treatment for one week
* Refusal to participate

Where it's running

• CHRU de Brest
  Brest, France Recruiting
• CH de SAINT ANNE
  Paris, France Recruiting
• Meunier Sophie
  Caen, France Not yet recruiting

Study contacts

• Study coordinator: Christophe LEMEY, Doctor
• Email: christophe.lemey@chu-brest.fr
• Phone: 02 98 01 52 06

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

• Add CBD to antipsychotic treatment for first-episode psychosis to see if it helps more than placebo

  This study tests whether adding cannabidiol (CBD) to ongoing antipsychotic treatment helps people with a first episode of psychosis who haven’t fully responded to their first antipsychotic, compared with a placebo.

  Recruiting at 2 sites Phase 3 University of Oxford · Vienna and 16 other locations · NCT06778564

• Comparing Avatar Therapy and Cognitive Behavioural Therapy for Hearing Voices

  This study is testing whether Avatar Therapy can help people with long-term hearing voices feel better compared to standard Cognitive Behavioural Therapy.

  Recruiting Swinburne University of Technology · Hawthorn, Victoria · NCT05982158

• Investigating cognitive function in psychosis patients and cannabis users

  This study is testing how taking a break from cannabis for 28 days affects thinking skills and brain activity in people with psychosis and those who use cannabis but don’t have mental health issues.

  Recruiting Douglas Mental Health University Institute · Montreal, Quebec · NCT05445180

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.